weight loss market reports

2022 Census Data Published: Commercial Weight Loss Industry Statistics

April 24, 2025 The U.S. Census of Service Industries is performed every 5 years, with the last government survey performed in 2022. Commercial weight loss companies (“diet & reducing centers”) are classified under NAICS code 812191 (other personal services). Establishment and firms data for this industry have just been released (see census.gov). This information is […]

2022 Census Data Published: Commercial Weight Loss Industry Statistics Read More »

Novo Nordisk Submits Weight Loss Pill for FDA Approval

News / John LaRosa

April 24, 2025 Novo Nordisk asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this year, a spokesperson confirmed. The company first reported in 2023 that the drug, an oral form of semaglutide, succeeded in a Phase 3 trial, helping people on the highest

Novo Nordisk Submits Weight Loss Pill for FDA Approval Read More »

$5 Billion U.S. Meal Replacements Market Survives GLP-1s Competition

News / John LaRosa

April 22, 2025 Marketdata LLC has just released a new market study: “The U.S. Meal Replacements Market: Retail & MLM Channels”, April 2025. This 77-page report analyses the meal replacements and retail appetite suppressants market in the U.S. The $5.1 billion U.S. meal replacements market has held up fairly well the past few years, despite

$5 Billion U.S. Meal Replacements Market Survives GLP-1s Competition Read More »

Robard Begins Selling Diet Foods Direct to Consumers

News / John LaRosa

April 2, 2025 Robard, the medical weight loss company, has begun selling its shakes, puddings, soups and beverages direct to the public via a new website. These products are part of its New Direction program. This is a departure from its long-standing policy where you had to sign up for the program to get access

Robard Begins Selling Diet Foods Direct to Consumers Read More »

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion

News / John LaRosa

March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »

Weight Loss Market’s Leaders Lost At Least $971 Million in 2023

News / John LaRosa

Sept. 24, 2024 Marketdata LLC, DietBusinessWatch.com’s parent), estimates that the top competitors in the U.S. weight loss market lost at least $971 million in revenues last year, due to the juggernaut of GLP-1 medications. This is a huge transfer of sales from commercial and retail weight loss programs and product segments to medical programs. Here’s

Weight Loss Market’s Leaders Lost At Least $971 Million in 2023 Read More »

Eli Lilly Offers Access To Zepbound via Amazon

News / John LaRosa

March 14, 2024 The U.S. pharmaceutical giant Eli Lilly is partnering with Amazon to help distribute its prescription drugs, notably its new weight loss treatment called Zepbound. Eli Lilly is using Amazon Pharmacy to distribute Zepbound to people’s homes through the drug maker’s new direct-to-consumer program. Going forward, Amazon Pharmacy will deliver drugs from Eli

Eli Lilly Offers Access To Zepbound via Amazon Read More »

U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs

News / John LaRosa

March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated

U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »

Ozempic Boom Is Hurting Weight Loss Coaches

News / John LaRosa

Jan. 11, 2024 The pandemic had significant effects on the way commercial weight loss companies operate, along with the explosive demand for GLP-1 obesity drugs such as Ozempic, Wegovy, and Mounjaro. Marketdata estimates that between Medifast, Weight Watchers, Jenny Craig, and Noom, at least 26,500 weight loss coaches have lost their jobs since 2020. Here’s

Ozempic Boom Is Hurting Weight Loss Coaches Read More »

Obesity Drug Sales Continue To Soar

News / John LaRosa

Sept. 13, 2023 On August 8, Lilly reported that its second-quarter income jumped 85% from the same period a year ago, driven in large part by Mounjaro, which generated $979.7 million in sales for the quarter, compared to $16 million in the year-ago period and $569 million in the first quarter of this year. In

Obesity Drug Sales Continue To Soar Read More »

(813) 971-8080